Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
about
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective studyMaintenance therapy for advanced non-small cell lung cancer (NSCLC)Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Ovine pulmonary adenocarcinoma: a large animal model for human lung cancerProtein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutationSequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation.Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study.Ginkgo biloba extract decreases non-small cell lung cancer cell migration by downregulating metastasis-associated factor heat-shock protein 27.Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancerThe efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.Gefitinib in non-small-cell lung cancer-an old lesson new re-visitedGefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.NQO1 protein expression predicts poor prognosis of non-small cell lung cancersHeat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer.Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Unexpected responses to EGFR inhibition in NSCLC.Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in SwedenThe effect of ribosomal protein S15a in lung adenocarcinoma.Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.PET/CT in therapy evaluation of patients with lung cancer.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.High cofilin-1 levels correlate with cisplatin resistance in lung adenocarcinomas.Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma.
P2860
Q21132047-B0DD202C-0AB7-48E3-BE6D-B498049B675EQ24186793-16F701E7-3FEA-47DA-81B0-566DF55EBEC6Q28082919-B6490CC5-AE85-4F4D-8DD8-5EAD9CCFD68CQ28088774-25CD9F90-5BDD-4EC1-B7F9-9811D1A49BD7Q33356339-3FA0E209-80A5-49AD-9FF6-193817E42720Q33438129-D4CC8C90-BDA6-497E-BBBD-B3F90DF661A4Q33955857-EEAD1F9D-7737-4A06-A422-770627D42E41Q33995172-E9E1C215-AABC-430B-9977-340320C97937Q34013434-EA852B00-C765-47F0-A5AB-2F7292A127D8Q34733257-81DF1619-4C06-4CDE-82C3-B0803AE539E5Q35117661-CC298C60-0B6D-47EE-AC2F-43FA7E2F72ADQ35120842-DF11E0F9-A0FC-4D61-9F62-50375866B04EQ35164824-DE186215-DF8F-429B-BAA3-C50796EBF22CQ35200450-C42FC03C-EBF2-43D0-919B-4F9D8F64F07AQ35345489-620BCB09-683A-4434-8A1A-6F7D55E5B813Q35409789-AFB1AC62-F928-4662-8BE8-5DA25D85799DQ35758521-1FC29DD7-AC85-4EED-BE00-59FE0D0E744AQ35920966-C4112646-DFC8-4090-9623-8D79D60CEBB8Q35970561-F87068E6-5B64-40E8-B020-7DD047689F95Q36378879-B27A163C-FF7C-4D6E-BC21-0AD182FC1161Q36437538-72F6A262-39D2-4E06-937D-6D9DA94303C4Q36691277-600E181B-DF44-41AD-8D57-C8FC16B39461Q38169157-209BE2DD-6C4D-4482-BA16-D8C46E69B36EQ38202189-4FF11C52-0BE1-4ED3-A979-EBA90AC70CAAQ38262804-67882F82-4F90-4C6C-9138-6ABA52E10202Q38289406-E285D692-2FAB-47CA-9669-E1BC25884643Q38471484-B7B092D0-D921-4DB2-BE95-72D251AC8220Q38834921-DC30662B-9892-40B2-8CEC-8017B5D2664DQ39098144-CC236FD1-14F0-4020-A5C1-5945629380E9Q51168062-00371E8D-AF0F-4855-AB61-DE0EAA4F1EA1Q53367071-52F5FFAA-5208-44C6-92B1-07BB80EC9813Q54329048-0F5AFF3E-19FE-4037-A566-2C7E6B7BE6EAQ54385410-25894997-A0A4-4B06-ADF6-A0C18DB1537F
P2860
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@ast
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@en
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@nl
type
label
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@ast
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@en
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@nl
prefLabel
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@ast
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@en
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@nl
P2093
P2860
P31
P921
P3181
P1433
P1476
Gefitinib or erlotinib as main ...... ng cancer: a systematic review
@en
P2093
Lingjun Zhu
Renhua Guo
Xiaofeng Chen
Yingying Qian
Yiqian Liu
Yongmei Yin
Yongqian Shu
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0059314
P407
P5008
P577
2013-01-01T00:00:00Z
2013-03-21T00:00:00Z